Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Joyce Nutt

Newcastle AuthorsTitleYearFull text
Professor Ruth Plummer
Dr Jane Margetts
Professor John Lunec
Dr Joyce Nutt
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker2015
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Mike Cole
Professor Ruth Plummer
et al.		Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy2010
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Amy Quinn
Professor Hilary Calvert
et al.		The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy2010
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Professor Ruth Plummer
Professor Hilary Calvert
et al.		Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis2009
Dr Joyce Nutt
Kieran O'Toole
Professor John Lunec
Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines2009
Dr Joyce Nutt
Professor John Lunec
The wide variation in response of mesothelioma cell lines to pemetrexed and lack of relationship to presence of folate receptor alpha (Fra)2009
Dr Joyce Nutt
Kilian Mellon
Professor John Lunec
hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours2007
Dr Joyce Nutt
Henry Lazarowicz
Kilian Mellon
Professor John Lunec
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP22004
Garrett Durkan
Dr Joyce Nutt
Colin Marsh
Dr Mary Robinson
Professor David Neal
et al.		Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer2003
Dr Joyce Nutt
Garrett Durkan
Kilian Mellon
Professor John Lunec
Matrix metalloproteinases (MMPs) in bladder cancer: The induction of MMP9 by epidermal growth factor and its detection in urine2003
Garrett Durkan
Dr Joyce Nutt
Professor David Neal
Professor John Lunec
Kilian Mellon
Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder2001
Dr Joyce Nutt
Garrett Durkan
Professor John Lunec
Matrixmetalloproteinase stimulation in bladder tumour cell lines and elevated levels in the urine of bladder tumour patients.1999
Dr Joyce Nutt
Kilian Mellon
Dr Khaver Qureshi
Professor John Lunec
Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours1998
Dr Joyce Nutt
Professor John Lunec
Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells1996
Dr Joyce Nutt
Professor John Lunec

Phorbal ester and bryostatin effects on growth and the expression of estrogen and TGF-beta in breast-tumor cells

1991
12